170 related articles for article (PubMed ID: 33468209)
1. Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study.
Alhenc-Gelas M; Cabel L; Berger F; Delaloge S; Frenel JS; Levy C; Firmin N; Ladoire S; Desmoulins I; Heudel PE; Dalenc F; Loirat D; Dubot C; Vuagnat P; Deluche E; Mokdad-Adi M; Patsouris A; Annic J; Djerroudi L; Lavigne M; Pierga JY; Coppo P; Bidard FC
Breast Cancer Res; 2021 Jan; 23(1):9. PubMed ID: 33468209
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology of tumour-induced microangiopathic haemolytic anaemia.
Chalasani P; Segar JM; Marron M; Stopeck A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26744538
[TBL] [Abstract][Full Text] [Related]
3. [Breast cancer-related thrombotic microangiopathy: A review].
Alhenc-Gelas M; Bidard FC
Bull Cancer; 2021; 108(7-8):730-739. PubMed ID: 34052032
[TBL] [Abstract][Full Text] [Related]
4. Microangiopathic hemolytic anemias (MAHA) in cancer. A case report and review.
Nordström B; Strang P
Anticancer Res; 1993; 13(5C):1845-9. PubMed ID: 8267391
[TBL] [Abstract][Full Text] [Related]
5. Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study.
Lam R; Tarangelo N; Wang R; Horibe M; Grimshaw AA; Jain D; Haffar S; Bazerbachi F; Kunz PL; Li DK
Oncologist; 2022 Sep; 27(9):751-759. PubMed ID: 35589098
[TBL] [Abstract][Full Text] [Related]
6. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases.
Lechner K; Obermeier HL
Medicine (Baltimore); 2012 Jul; 91(4):195-205. PubMed ID: 22732949
[TBL] [Abstract][Full Text] [Related]
7. Cancer-related microangiopathic hemolytic anemia in patients with advanced gastric cancer: A retrospective single-center analysis.
Berger AK; Allgäuer M; Apostolidis L; Schulze-Schleithoff AE; Merle U; Jaeger D; Haag GM
World J Gastrointest Oncol; 2020 Nov; 12(11):1288-1295. PubMed ID: 33250961
[TBL] [Abstract][Full Text] [Related]
8. Microangiopathic Haemolytic Anaemia in a Young Male Patient With Oesophageal Carcinoma.
Ndlovu S; Czako B
Cureus; 2021 Aug; 13(8):e17479. PubMed ID: 34603868
[TBL] [Abstract][Full Text] [Related]
9. Microangiopathic haemolytic anaemia (maha) caused by non O157:H7 E-coli.
Shahid M
J Pak Med Assoc; 2017 Jun; 67(6):962-963. PubMed ID: 28585607
[No Abstract] [Full Text] [Related]
10. Microangiopathic hemolytic anemia associated with metastatic breast cancer: case report and literature review.
Takabatake D; Oishi K
Springerplus; 2016; 5(1):684. PubMed ID: 27350919
[TBL] [Abstract][Full Text] [Related]
11. Microangiopathic haemolysis associated with occult carcinoma.
Collins PW; Jones L; Pocock C; Newland AC
Clin Lab Haematol; 1991; 13(3):245-9. PubMed ID: 1794226
[TBL] [Abstract][Full Text] [Related]
12. Post-partum occurrence of Wunderlich syndrome and microangiopathic haemolytic anaemia (MAHA): a case report.
Swaminathan N; Sedhom R; Shahzad A; Azmaiparashvili Z
J Community Hosp Intern Med Perspect; 2021 Mar; 11(2):277-279. PubMed ID: 33889338
[TBL] [Abstract][Full Text] [Related]
13. Microangiopathic hemolytic anemia (MAHA) as paraneoplastic syndrome in metastasized signet ring cell carcinomas: case reports and review of the literature.
Arkenau HT; Müssig O; Buhr T; Jend HH; Porschen R
Z Gastroenterol; 2005 Aug; 43(8):719-22. PubMed ID: 16088769
[TBL] [Abstract][Full Text] [Related]
14. [MICROANGIOPATHIC HEMOLYTIC ANEMIA AS PRESENTING SYMPTOM OF GASTRIC ADENOCARCINOMA].
Dally N; Kashlikov M; Farah R
Harefuah; 2016 Apr; 155(4):212-4, 255. PubMed ID: 27323535
[TBL] [Abstract][Full Text] [Related]
15. Microangiopathic haemolytic anaemia and systemic vasculitis.
Ross CN; Reuter H; Scott D; Hamilton DV
Br J Rheumatol; 1996 Apr; 35(4):377-9. PubMed ID: 8624643
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
17. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
18. In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study.
Johansson ALV; Trewin CB; Fredriksson I; Reinertsen KV; Russnes H; Ursin G
Breast Cancer Res; 2021 Feb; 23(1):17. PubMed ID: 33526044
[TBL] [Abstract][Full Text] [Related]
19. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
